Abstract
In contrast to traditional pharmacological treatments for hypertension, immunotherapies serve as promising alternatives as they are low-cost and afford better patient compliance. In this study, a chimeric protein targeting Angiotensin II via genetic fusion to a nucleocapsid antigen from Hepatitis B virus (HBcAg), serving as a carrier, is designed. This candidate immunogen designated as HBcAgII has been expressed in the alga specie Chlamydomonas reinhardtii, serving as an attractive vaccine expression system and delivery host. This alga can be grown on minimal media under controlled environmental conditions, and can serve as a safe oral delivery vehicle. Transgenic C. reinhardtii lines have been developed, and the expected recombinant protein has been detected by Western blot and ELISA analyses. Levels of expression of this recombinant protein in some transgenic lines have reached 0.05 % of total soluble protein. The immunogenic properties of the HBcAgII algae-derived antigen will be assessed.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Ambühl PM, Tissot AC, Fulurija A, Maurer P, Nussberger J, Sabat R, Nief V, Schellekens C, Sladko K, Roubicek K, Pfister T, Rettenbacher M, Volk HD, Wagner F, Müller P, Jennings GT, Bachmann MF (2007) A vaccine for hypertension based on virus-like particles: preclinical efficacy and phase I safety and immunogenicity. J Hypertens 25:63–72
Bradford MM (1976) A rapid and sensitive method for the quantification of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72:248–254
Bramlage P, Hasford J (2009) Blood pressure reduction, persistence and costs in the evaluation of antihypertensive drug treatment: a review. Cardiovasc Diabetol 8:18
Campos-Quevedo N, Rosales-Mendoza S, Paz-Maldonado LMT, Martinez-Salgado L, Guevara-Arauza JC, Soria-Guerra RE (2012) Production of milk-derived bioactive peptides as precursor chimeric proteins in chloroplasts of Chlamydomonas reinhardtii. Plant Cell Tissue Organ Cult 113:217–225
Casu R, Selivanova A, Perroux JM (2012) High-throughput assessment of transgene copy number in sugarcane using real-time quantitative PCR. Plant Cell Rep 31:167–177
Hahne G, Horn M, Reski R (2011) Plant biotechnology in support of the Millennium Goals. Plant Cell Rep 30:245–247
Kumar SV, Misquitta RW, Reddy VS, Rao BJ, Rajam MV (2004) Genetic transformation of the green alga—Chlamydomonas reinhardtii by Agrobacterium tumefaciens. Plant Sci 166:731–738
Leon R, Fernandez E (2007) Nuclear transformation of eukaryotic microalgae: historical overview, achievements and problems. Adv Exp Med Biol 616:1–11
Maurer P, Bachmann MF (2010) Immunization against angiotensins for the treatment of hypertension. Clin Immunol 134:89–95
Ou X, Guo L, Wu J, Mi K, Yin N, Zhang G, Li H, Sun M (2013) Construction, expression and immunogenicity of a novel anti-hypertension angiotensin II vaccine based on hepatitis A virus-like particle. Hum Vaccin Immunother 14:9
Pniewski T, Kapusta J, Bociąg P, Wojciechowicz J, Kostrzak A, Gdula M, Fedorowicz-Strońska O, Wójcik P, Otta H, Samardakiewicz S, Wolko B, Płucienniczak A (2011) Low-dose oral immunization with lyophilized tissue of herbicide-resistant lettuce expressing hepatitis B surface antigen for prototype plant-derived vaccine tablet formulation. J Appl Genet 52:125–136
Rasala BA, Lee PA, Shen Z, Briggs SP, Mendez M, Mayfield SP (2012) Robust expression and secretion of Xylanase1 in Chlamydomonas reinhardtii by fusion to a selection gene and processing with the FMDV 2A peptide. PLoS ONE 7(8):e43349
Roldão A, Mellado MC, Castilho LR, Carrondo MJ, Alves PM (2010) Virus-like particles in vaccine development. Expert Rev Vaccines 9:1149–1176
Rosales-Mendoza S (2013) Future directions for the development of Chlamydomonas-based vaccines. Expert Rev Vaccines 12:1011–10119
Rosales-Mendoza S, Paz-Maldonado LM, Soria-Guerra RE (2012) Chlamydomonas reinhardtii as a viable platform for the production of recombinant proteins: current status and perspectives. Plant Cell Rep 31:479–494
Ryan MD, King AM, Thomas GP (1991) Cleavage of foot-and-mouth disease virus polyprotein is mediated by residues located within a 19 amino acid sequence. J Gen Virol 72:2727–2732
Sambrook J, Fritsch EF, Maniatis T (1989) Molecular cloning: a laboratory manual, 2nd edn. Cold Spring Harbor Laboratory Press, Cold Spring Harbor
Scotti N, Rybicki EP (2013) Virus-like particles produced in plants as potential vaccines. Expert Rev Vaccines 12:211–224
Shepherd CT, Moran Lauter AN, Scott MP (2009) Determination of transgene copy number by real-time quantitative PCR. Methods Mol Biol 526:129–134
Shimizu Y (1996) Microalgal metabolites: a new perspective. Annu Rev Microbiol 50:442–445
Soria-Guerra RE, Moreno-Fierros L, Rosales-Mendoza S (2011) Two decades of plant-based candidate vaccines: a review of the chimeric protein approaches. Plant Cell Rep 30:1367–1382
Specht E, Miyake-Stoner S, Mayfield S (2010) Micro-algae come of age as a platform for recombinant protein production. Biotechnol Lett 32:1373–1383
Surzycki R, Greenham K, Kitayama K, Dibal F, Wagner R, Rochaix JD, Ajam T, Surzycki S (2009) Factors effecting expression of vaccines in microalgae. Biologicals 37:133–138
Tissot AC, Maurer P, Nussberger J, Sabat R, Pfister T, Ignatenko S, Volk HD, Stocker H, Muller P, Jennings GT, Wagner F, Bachmann MF (2008) Effect of immunization against angiotensin II with CYT006-AngQb on ambulatory blood pressure: a double-blind, randomised, placebo-controlled phase II a study. Lancet 371:821–827
WHO (2009) Global health risks: mortality and burden of disease attributable to selected major risks. Geneva, World Health Organization
WHO (2011) Bulletin of the World Health Organization. Geneva, World Health Organization, 89:324–325
Wirz H, Sauer-Budge AF, Briggs J, Sharpe A, Shu S, Sharon A (2012) Automated production of plant-based vaccines and pharmaceuticals. J Lab Autom 17:449–457
Yusibov V, Streatfield SJ, Kushnir N (2011) Clinical development of plant-produced recombinant pharmaceuticals. Vaccines, antibodies and beyond. Hum Vaccin 7:313–321
Acknowledgments
This work was supported by CONACYT grants #102109 to SRM and #151480 to RESG. We thank Dr. Manfredo Seufferheld of the University of Illinois campus Urbana-Champaign (UIUC) for the donation of the C. reinhardtii 137 (mt+), and Dr. Omar González-Ortega for lending electrophoresis supplies.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Soria-Guerra, R.E., Ramírez-Alonso, J.I., Ibáñez-Salazar, A. et al. Expression of an HBcAg-based antigen carrying angiotensin II in Chlamydomonas reinhardtii as a candidate hypertension vaccine. Plant Cell Tiss Organ Cult 116, 133–139 (2014). https://doi.org/10.1007/s11240-013-0388-x
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11240-013-0388-x